*progr antifosfolidi - aps · general information venue palazzo dei congressi p.zza adua, 1 50123...

2

12th INTERNATIONAL CONGRESS ON ANTIPHOSPHOLIPID ANTIBODIES

UNDER THE AEGIS OF S.I.R. - Società Italiana di Reumatologia Onlus

C.R.O.I. - Collegio dei Reumatologi Ospedalieri Italiani S.I.A.I.C. - Società Italiana di Allergologia e Immunologia Clinica

S.I.I.C.A. - Società Italiana di Immunologia, Immunologia Clinica e Allergologia S.I.M.I. - Società Italiana di Medicina Interna

ChairpersonsP.L. Meroni Italy A. Tincani Italy

Local Organizing CommitteeI. Cetin, Italy B. Acaia, Italy

G. Balestrieri, Italy S. Bombardieri, Italy

S. Di Masso, ItalyA. Lojacono, ItalyF. Tedesco, ItalyG. Valesini, Italy

International Advisory BoardJ. Arnout, Belgium

R.A. Asherson, South Africa M.C. Boffa, France D.W. Branch, USA

R.L. Brey, USAR. Cervera, Spain

P.G. De Groot, The NetherlandsR.H.W.M. Derksen, The Netherlands

T. Exner, Australia M. Galli, Italy

E.N. Harris, JamaicaG.R.V. Hughes, UK

M.A. Khamashta, UKT. Koike, Japan

S.A. Krilis, AustraliaR.G. Lahita, USA R. Levy, Brazil

M.D. Lockshin, USAS. Machin, UK

G.A. McCarty, USAJ.A. McIntyre, USA

V. Pengo, ItalyM. Petri, USA

S.S. Pierangeli, USAJ.C. Piette, France

R. Rai, UKJ. Rand, USA

J. Rauch, CanadaN.R. Rose, USA

R.A.S. Roubey, USAY. Shoenfeld, Israel

P. Von Landenberg, GermanyW.A. Wilson, USAP. Youinou, France

5th INTERNATIONAL CONFERENCE ON SEX HORMONES, PREGNANCY AND THE RHEUMATIC DISEASES

PresidentsM. Cutolo, Italy

M. Matucci Cerinic, Italy

Local Organizing CommitteeR. Abbate, Italy R. Cimaz, Italy M. Costa, Italy

S. De Carolis, Italy A. Doria, Italy F. Falcini, Italy

M Galeazzi, Italy G. Mello, Italy

C. Montecucco, Italy M. Mosca, Italy M. Motta, Italy

International Steering CommitteeW. Branch, USAA. Brucato, ItalyC. Gordon, UKG. Hughes, UK

M. Khamashta, UKM. Lockshin, USAP. Meroni, Italy

M. Østensen, SwitzerlandA. Parke, USA

A. Tincani, Italy

3

GENERAL INFORMATION GENERAL INFORMATION

VenuePalazzo dei CongressiP.zza Adua, 150123 Florence, Italy

Congress SecretariatOIC srlVia Fatebenfratelli, 1920121 Milan, ItalyTel. +39 02 65 71 200Fax +39 02 65 71 270E-mail [email protected]

Registration and Hotel Accommodation DepartmentOIC srlViale G. Matteotti, 7 50121 Florence, ItalyTel. +39 055 50351Fax +39 055 5001912E-mail [email protected]

Registration fees (VAT incl.)

12TH

International Congress on Antiphopsholipid Antibodies - April 18/19/20, 2007Participants € 540.00Students/young Doctors (u.35 y.o.)* € 240.00

5TH

International Conference on Sexual Hormones, Pregnancy And Rheumatic DiseasesApril 20/21, 2007Participants € 350.00Students/young Doctors*(u.35 y.o.)* € 240.00

Combined registration fees (April 18/19/20/21, 2007)Participants € 660.00Students/young Doctors*(u.35 y.o.)* € 360.00* certification required

The registration fees include:- access to all scientific session and exhibition;- congress folder including program and abstract book;- coffee break and lunches.

BadgeEach participant will receive a name badge upon check-in at the registration desk.The badge will be the official meeting document and should be worn at all time inorder to gain entry into the meeting rooms.

Catering facilitiesLunches and coffee breaks are included in the registration fee.

4

Social dinnerOn April 19, a Social Dinner will take place at the Grand Hotel Baglioni. € 80,00 (VAT included) per person.

Certificate of attendanceRegularly registered participants will receive a certificate of attendance.

InsuranceThe Congress Organizers does not assume any liability for personal injuries sustainedor loss of, or damage to, property belonging to congress participants (or their accom-panying persons), either during or as result of the congress.Participants are requested to make their own arrangements with respect to health andtravel insurance.Members of the European Community are advised to issue in their Country the healthinsurance form E111.

Easy access to FlorenceBy air: There are frequent direct flights to all the most important European cities as well as convenient intercontinental connections. Florence Airport "Amerigo Vespucci" isonly 5 km from downtown. Bus and taxi transportation is available between the airportand city centre. There is also Pisa Airport "Galileo Galilei" served by several interna-tional airlines, connected to Florence by a shuttle train operating every hour. The triplasts approximately 1 hour.By car: Florence is also centrally situated along the major north-south motorway. TheA1 "Autostrada del Sole" with its four exits available and the A11 "Autostrada del Mare".By train: Eurostar trains connect Florence with Milan (2 hrs and 45 min approxima-tely) and Rome (1 hr and 45 min approximately). The main railway station in Florenceis “S. Maria Novella” which is very near to the congress venue.

Transportation to the congress venueFrom the airport: a bus connection (Volainbus) is operating from the airport to the citycentre (main station) every 20-25 minutes.From the main train station: from the main train station you can reach the congresscentre in 5 minutes walking.Taxis: Taxis in Florence can be ordered by phone (Tel. 055 4242 or 4390) or found atthe official taxi stand. You cannot stop a taxi on the road.Bus: Florence has a comprehensive network of local bus routes. Most of them stop atthe main railway station and therefore near to the convention venue. Bus tickets canbe purchased at most coffee bars and kiosks. Fare is € 1,20 multiple trips, valid up to70 minutes.

Car parkingThere are several paying parking areas around the congress centre.

Weather The weather in Florence in April is usually mild. The average temperature is 20°C. Donot forget a raincoat or umbrella for possible heavy showers.

GENERAL INFORMATION GENERAL INFORMATION

5

SCIENTIFIC INFORMATIONSCIENTIFIC INFORMATION

Official languageThe official language of the Congress is English.No simultaneous translation will be provided.

Slide centreAll the meeting rooms will be equipped only with a digital projector connected to a per-sonal computer. No traditional slide projection and no connection will be available for personal laptopsin the meeting rooms Speakers are requested to use Power Point for Windows (or Mac/Apple); the files con-taining the presentation must be to be delivered using a floppy disk, CD, flash card ormemory stick at the slide centre, available on the premises, at least 45 minutes priorto their talks.We strongly suggest that all presentations do not exceed 20 MB, to avoid any delayduring scientific sessions.

Certificate of attendanceThe certificate of attendance will be given to all registered participants who will requestit at the Organizing Secretariat desk.

AccreditationThe Italian Ministry of Health has granted the following credits:April 18/19, 4 creditsApril 20 3 creditsApril 21 not yet received

PostersThe posters should be displayed as follows: - on April 18 and 19, 2007 from 8.30 to 18.30 - Posters from P1 to P103- on April 20 and 21, 2007 from 8.30 to 18.30 - Posters from P104 to P181Posters will be discussed during the lunch breaks: one of the Authors should be pre-sent during the relevant session to answer the questions about his abstract.The Organizing Secretariat will remove the poster left behind after the end of the dayand assumes no responsibility for damaged or lost artwork.

AESKU.KIPP INSTITUTE Prize for Young InvestigatorsOn April 19, 2007, the AESKU.KIPP INSTITUTE Prize for Young Investigators will beawarded for the first time during the "12th International Congress on AntiphospholipidAntibodies".The AESKU.KIPP INSTITUTE focuses on the research in the causes of autoimmune dis-eases. Based on this background it is primarily interested in funding basic, academicresearch. It further focuses on clinical research cooperations to develop therapeuticconcepts and to design assays for early and reliable diagnostics.The AESKU.KIPP INSTITUTE, located in Wendelsheim, Germany, considers the prize anexpression of its philosophy. One of the goals is to stress the importance of researchin autoimmune diseases and the progress in this field. With the donation of this prizethe AESKU.KIPP INSTITUTE intends specifically to foster young scientists, who distin-guish themselves for their excellence in research in the field of autoimmunity.The AESKU.KIPP INSTITUTE offers two grants to Young Investigators, including a prizemoney of 2,500 $ each, on the basis of the scientific merit of the proposed abstractand the relevance of the research aimed to improve our understanding of autoimmu-ne diseases. The main criterion for evaluation of the application is the potential for theproposed research to improve the general understanding, diagnosis, prognosis andtherapy of the disease process in autoimmune diseases. According to the goal of theAESKU.KIPP INSTITUTE to grant the work of promising young researchers applicantsshould be not older than 35 years of age.

6

8

April 18 WednesdayApril 18 Wednesday SCIENTIFIC SCIENTIFIC

8.30/13.30 Registration

14.00/16.00 APL TARGETS AND MEDIATED EFFECTS (With the unconditional grant of Menarini Diagnostics)Chairmen: S.S. Pierangeli (USA), F. Tedesco (Italy)

PL-binding proteins

14.00 Beta 2 glycoprotein IS.A. Krilis (Australia)

14.10 Antiprothrombin antibody and thrombin generationT. Atsumi (Japan)

Target Cells

14.20 Monocytes in the antiphospholipid syndrome: a critical role for early growth response gene-1R.A.S. Roubey (USA)

14.30 Endothelium as target for APLP.L. Meroni (Italy)

Experimental in vivo models

14.40 Molecular mimicryM. Blank

14.50 In vivo modelsS.S. Pierangeli (USA)

15.00 An induced model of murine SLE: from anti-phospholipid to anti-DNA antibodies J. Rauch (Canada)

15.10 Discussion


ORAL PRESENTATION SESSIONChairmen: T. Koike (Japan), V. Pengo (Italy)

15.20 P175 Anti-ß2-GPI antibodies induce monocyte release of TNFα and tissue factor by signal transduction pathways involving lipid raftsC. Alessandri, M. Sorice, A. Longo, A. Capozzi, T. Garofalo, R. Misasi, F. Conti, C. Croia, B. Buttari, R. Biganò, E. Ortona, G. Valesini (Italy)

15.30 P171 Platelets express three 3 different splice variants of ApoER2 of which ApoER2∆4-5 is the most abundant. Dimeric ß2-GPI binds toLDL-binding domain 1 of ApoER2M.T.T. Pennings, R.H.W.M. Derksen, R.T. Urbanus, P.G. de Groot (The Netherlands)

15.40 P158 Anti-ß2-glycoprotein I antibodies in complex with ß2-glycoprotein I can activate platelets via glycoprotein Ib-IX-VB. Giannakopoulos, T. Shi, X. Yan, P. Yu, M.C. Berndt, R.K. Andrews, J. Rivera, G.M. Iverson, K.A. Cockerill , M.D. Linnik, S.A. Krilis (Australia, USA)

15.50 Discussion

16.00/16.15 Coffee break

16.15/17.30 ROUND TABLE. INFLAMMATORY EVENTS: YES OR NOT? Chairmen: P. Parronchi (Italy), N. Rose (USA)

16.15 Is there any evidence for an inflammatory process associated with thrombosis induced by anti-phospholipid antibodies?F. Tedesco (Italy)

16.25 Inflammatory events? NoJ. Rand (USA)

16.35 Discussion

9

April 18 WednesdayApril 18 Wednesday PROGRAM PROGRAM


10

April 18 WednesdayApril 18 Wednesday

ORAL PRESENTATION SESSIONChairmen: M. Galeazzi (Italy), P. Von Landerberg (Germany)

16.45 P154 Expression and regulation of protease-activated receptors (PARs) in monocytes from patients with APSM.J. Cuadrado, P. Buendía, M.A. Aguirre, N. Barbarroja, A. Torres, F. Velasco, M.A. Khamashta, C.H. Lopez-Pedrera(UK, Spain)

16.55 P28 C-reactive protein in primary antiphospholipid syndromeP.R.J. Ames, A. Ciampa, G. Scenna, l. Antinolfi, L. Lopez, E. Matsuura (UK, Italy, USA, Japan)

17.05 P159 Signaling via both GPIbα and ApoER2`is required for platelet activation by dimeric ß2-glycoprotein IR.T. Urbanus, M.T.T. Pennings, R.H.W.M. Derksen, P.G. de Groot (The Netherlands)

17.15 Discussion

17.30/18.30 ROUND TABLE. APL AND ARTERIAL EVENTS: YES OR NOT?Chairmen: S. Bombardieri (Italy), D. Erkan (USA)

17.30 YesM. Khamashta (UK)

17.40 Not always P. De Groot (The Netherlands)

17.50 Discussion

ORAL PRESENTATION SESSION

18.00 P1 Beta 2 glycoprotein I dependent anti-phospholipid antibodies and myocardial infarction in young premenopausal women: a multicenter studyP.L. Meroni, A. Tincani, L. Foco, L. Bernardinelli, P.M. Mannucci (Italy)

18.10 P65 Study of anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patient with ischemic strokeA. Astrinidou-Vakaloudi, P. Papastergiou, E. Nanousi, V. Papakostantinou, B. Galanopoulou (Greece)

18.20 Discussion


SCIENTIFIC SCIENTIFIC

11

April 18 WednesdayApril 18 Wednesday

18.30/19.30 GENETIC OF APSChairmen: A. Tincani (Italy), W.A. Wilson (USA)

18.30 What we knowM. Galeazzi (Italy)

18.40 What we should knowM.E. Alarcón-Riquelme (Sweden)

18.50 Discussion


19.00 P50 CD45 exon 6 A138G polymorphism is associated with antiphospholipid syndrome T. Horita, H. Nakagawa, Y. Sakai, H. Kataoka, S. Yasuda, T. Atsumi, T. Koike (Japan)

19.10 P20 Factor V Leiden and prothrombin gene mutation are not associated with thrombosis in patients with antiphospholipid syndromeG. Espinosa, G. Claver, D. Tassies, J. Plaza, J.C. Reverter, R. Cervera (Spain)

19.20 Discussion

19.30 OPENING CEREMONY

Welcome addressA. Passaleva (Italy)

THE APS STORYN. Harris (Jamaica), A. Tincani (Italy), P.L. Meroni (Italy)


PROGRAM PROGRAM

12

April 19 ThursdayApril 19 Thursday SCIENTIFIC SCIENTIFIC

9.00/11.00 THERAPEUTICAL INTERVENTIONChairmen: G.R.V. Hughes (UK), G. Valesini (Italy)

9.00 Tips and traps of keeping your patient's INR stableR.A. Levy (Brazil)

9.10 Additional therapies P. Youinou (France)

9.20 Discussion

ORAL PRESENTATION SESSIONChairmen: P.L. Meroni (Italy), D. Erkan (USA)

9.30 P117 Successful outcome in 67 APS pregnancies treated with coumadinN.R. Jesús, R.A. Levy, G.R.R. Jesús, V.S. Vilela, A.M.H. Lima, E.M.N. Albuquerque (Brazil)

9.40 P70 Antiphospholipid antibody (aPL) reduction in patients treated withlow dose aspirin (LDA) & hydroxychloroquine (HCQ): recursive partitioning analysis of a large antiphospholipid syndrome cohortG.A. McCarty, T.E. Cason (USA)

9.50 P67 Effect of rosuvastatin on vascular cell adhesion molecule 1 (VCAM-1) expression by human endothelial cells exposed to antiphospholipid syndrome serum in an in vitro modelL.A. Martínez-Martínez, M.C. Amigo, A. Orozco, M. Núñez, O. Nuevo, I. Rodríguez, G. Medina, G. Ceballos, L.J. Jara (Mexico)

10.00 P168 Effects of an inhibitor of nuclear factor-kappa B (NF-kB) on thrombogenic properties of antiphospholipid antibodies in vivo G. Montiel-Manzano, Z. Romay-Penabad, E. Papalardo, S.S. Pierangeli (USA)

10.10 P52 Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement T. Tison, P. Bagatella, M. Ciprian, A. Ruffatti, G. Luzzatto, F. Fabris, P. Marson, G. De Silvestro (Italy)

10.20 P26 Primary antiphospholipid syndrome patients consume more weekly warfarin than inherited thrombophilia patients at similar target INRP.R.J. Ames, A. Ciampa, G. Scenna, L. Iannaccone, M. Margaglione, V. Brancaccio (UK, Italy)

10.30 Discussion

10.45/11.00 Coffee break and poster viewing


11.00-12.00 ROUND TABLE. LONG FOLLOW-UP IN APL POSITIVEPATIENTS/SUBJECTS(with the unconditional grant of Instrumentation Laboratory)Chairmen: M. Petri (USA), A. Tincani (Italy)

11.00 Long follow-up in patients with antiphospholipid syndromeR. Cervera for The European aPL Forum (Spain)

11.10 Atherosclerosis and antiphospholipid antibodiesM. Petri (USA)

11.20 Discussion


11.30 P75 Cardiac valve replacement in APS patientsJ.G. Erdozain, M.V. Egurbide, M.C. Amigo, M.I. Segura, G. Espinosa, J.L. Pomar, I. Perez, M.A. Khamastha(Spain, UK, Mexico)

11.40 P32 Premature atherosclerosis and cardiovascular events (CVE) in patients with systemic lupus erythematosus (SLE) with or withoutantiphospholipid syndrome (APS) and lupus nephritis (LN)N.L. Kozlovskaya, S.Y. Serikova, E.M. Shilov (Russia)

11.50 Discussion

12.15/13.15 Lunch and poster viewing

13

April 19 ThursdayApril 19 Thursday PROGRAM PROGRAM



14

April 19 ThursdayApril 19 Thursday

13.15/15.15 NON TRADITIONAL CLINICAL MANIFESTATIONS(with the unconditional grant of Instrumentation Laboratory)Chairmen: R.H.W.M. Derksen (The Netherlands),V. Pengo (Italy)

13.15 “Subset” and variants of the antiphospholipid syndrome in 2007 R.A. Asherson (South Africa)

13.25 ADAMTS 13 deficiency as risk factor for thrombosis in APS S. Machin (UK)

13.35 CNS involvement Y. Shoenfeld (Israel)

13.45 Seronegative APS G. Valesini (Italy)

13.55 Kidney involvement A. Sinico (Italy)

14.05 Discussion

ORAL PRESENTATION SESSIONChairmen: P. de Groot (The Netherlands), P.L. Meroni (Italy)

14.25 P101 Antiphospholipid antibodies and central nervous system involvement: direct autoantibody binding to neuronal cellsT. Lavazza, A. Dipinto, M.O. Borghi, V. Usuelli, A. Bergamaschi, V. Zimarino, P.P. Chen, P.L. Meroni, A. Malgaroli (Italy, USA)

14.35 P16 Specific binding of antiphospholipid antibodies to defined white matter tracts in a mouse modelA. Katzav, I. Eshcoli, M. Blank, Y. Shoenfeld, J. Chapman(Israel)

14.45 P4 Cross-reactive epitope on β2GPI and saccharomyces cervisiae in patients with the antiphospholipid syndromeI. Krause, M. Blank, R. Cervera, J. Font, T. Matthias, A. Fraser, Y. Shoenfeld (Israel, Spain, Germany)

14.55 P97 Antinucleosome antibodies in primary antiphospholipid syndromeL. Andreoli, F. Pregnolato, R. Burlingame, V. Fanelli, F. Allegri, A. Radice, A. Sinico, A. Tincani, P.L. Meroni (Italy, USA)

15.05 Discussion



PROGRAM PROGRAM

15


15.30/16.45 ROUND TABLE. aPL DETECTION ASSAYS: THE REAL LIFE IN 2007(including assay standardization)(with the unconditional grant of Menarini Diagnostics)

Chairmen: M. Galli (Italy), J.A. McIntyre (USA)

15.30 How the assays should be used? Lupus anticoagulantV. Pengo (Italy)

15.40 How the assays should be used? Solid phase assaysG. Reber (Switzerland)

15.50 Discussion

ORAL PRESENTATION SESSIONChairmen: M. Sanmarco (France), A. Tincani (Italy)

16.00 P178 A novel surface plasmon resonance biosensor for the analysis of antiphospholipid antibodiesP.B. Luppa, J. Metzger (Germany)

16.10 P180 European multicenter evaluation of the ELISA for anti-phosphatidyl-ethanolamine antibodiesM. Sanmarco, G. Reber, A. Béziane, U. Gaipl, B. Gilburd, G. Massai, M. Meissner, Z. Ulcova-Gallova, D. Ponard, M.C. Boffa(France, Switzerland, Germany, Israel, Italy, Poland, Czech)

16.20 P161 Detection of anti-ß2-glycoprotein I antibodies: comparison of the results obtained with different antigen preparationsA. Cavazzana, V. Pengo, M. Tonello, F. Noventa, M.O. Borghi, C. Grossi, P.L. Meroni, G. Reber, A. Ruffatti (Italy, Switzerland)

16.30 Discussion



16


16.45/17.45 ROUND TABLE. PRIMARY PROPHYLAXIS THERAPY: ALWAYS OR JUST IN SOME CASES?(with the unconditional grant of Menarini Diagnostics)Chairmen: T. Barbui (Italy, M.D. Lockshin (USA)

16.45 AlwaysG. Ruiz-Irastorza (Spain)

16.55 In some casesD. Erkan (USA)

17.05 Discussion


17.15 P23 Is age a risk factor for the manifestation of the antiphospholipid syndrome?W. Miesbach, R. Hudek, G. Asmelash, B. Lugalio, I. Scharrer, R. Grossmann (Germany)

17.25 P102 First thrombotic event in patients with obstetric APSM. Nuzzo, A. Ceribelli, F. Allegri, G. Gorla, G. Balestrieri, R. Cattaneo, A. Tincani (Italy)

17.35 Discussion

17.45/19.00 PATIENTS' SESSION(with the unconditional grant of Aesku.Kipp Institute)

19.00/19.30 APS: THE WIDENING SPECTRUMLecture by G.R.V. Hughes (UK)Chairman: A. Passaleva (Italy)Open to patients and participants

19.30 AESKU.KIPP INSTITUTE PRIZE FOR YOUNG INVESTIGATORS T. Matthias (Germany), A. Tincani (Italy), P.L. Meroni (Italy),A. Passaleva (Italy)


PROGRAM PROGRAM

8.30/10.30 ANTIPHOSPHOLIPID DAMAGE TO THE FOETUS: FROM THROMBOSIS TO ADAPTIVE & INNATE IMMUNE RESPONSES (PATHOGENIC MECHANISMS)Chairmen: P.L. Meroni (italy), J. Rand (USA)

8.30 Complement: the new player? M.D. Lockshin (USA)

8.40 Target cells: just fetal or maternal cells? I. Cetin (Italy)

8.50 Heparin and ASA: should we reconsider their mechanism of action? R. Rai (UK)

9.00 Discussion

ORAL PRESENTATION SESSIONChairmen: M. Costa (Italy), Y. Shoenfeld (Israel)

9.10 P107 New damage mechanisms of antiphospholipid antibodies on trophoblast cells: inhibition of HB-EGF expressionN. Di Simone, S. D'Ippolito, P.L. Meroni, M.C. D'Alessio, F. Di Nicuolo, R. Castellani, A. Caruso (Italy)

9.20 P116 Antiphospholipid syndrome (APS) based on a history of recurrent miscarriage (APS/RM): the importance of cytogenetic analysisM.D. Stephenson, S. Wu (Canada, USA)

9.30 P109 Complement as a predictor of miscarriageM. Sugiura-Ogasawara, Y. Ozaki, T. Nakanishi, K. Nozawa, K. Aoki (Japan)

9.40 P147 Effects of a toll-like receptor antagonist and anti-annexin A2 antibodies on binding and activation of decidual cells by antiß2glycoprotein I antibodiesM.O. Borghi, E. Raschi, S. Scurati, C. Grossi, S.S. Pierangeli, P.L. Meroni (Italy, USA)

9.50 P104 Third-trimester fetal death associated to antiphospholipid syndrome and/or inherited thrombophilia: results of subsequent pregnancies with adjusted dose enoxaparin treatment plus aspirinC. Pappalardo, A. Sarto, M. Martínez, A. Falco, L. Mezzabotta, R.S. Pasqualini (Argentina)

10.00 P111 Applied protocol with group control for therapeutic clinical follow-up of antiphospholipid syndrome (APS) during pregnancyJ.O. Latino, D. Fernandez Romero, G. Bierfass, C. Becker, J.C. Nassif, C. Allami, J.J. Scali (Argentina)

10.10 Discussion


17

April 20 FridayApril 20 Friday


and

5th INTERNATIONAL CONFERENCE ON SEX HORMONES,PREGNANCY AND THE RHEUMATIC DISEASES

18

10.45/12.30 PATHOGENESIS OF THE ANTIPHOSPHOLIPID MEDIATED PREGNANCY COMPLICATIONS: INFERTILITY, MISCARRIAGE AND PREECLAMPSIAChairmen: I. Cetin (Italy), R. Lahita (USA)

10.45 Miscarriages versus fetal losses: different pathogenic mechanisms? W. Branch (USA)

10.55 Preeclampsia and HELLP: aPL-related pregnancy complications? A. Lojacono (Italy)

11.05 Infertility and aPL: updateH.J.A. Carp (Israel)

11.25 Discussion

ORAL PRESENTATION SESSIONChairmen: A. Lojacono (Italy), W. Branch (USA)

11.35 P148 Protection against inflammation- and antiphospholipid antibody-caused fetal loss by the chemokine decoy receptor D6Y. Martinez de la Torre, C. Buracchi, E.M. Borroni, J. Dupor, R. Bonecchi, M. Nebuloni, F. Pasqualini, A. Doni, E. Lauri, C. Agostinis, R. Bulla, D.N. Cook, B. Haribabu, P.L. Meroni, D. Rukavina, L. Vago, F. Tedesco, A. Vecchi, S.A. Lira, M. Locati, A. Mantovani (Italy, USA, Croatia)

11.45 P181 Antiphospholipid antibodies in women experiencing repeated in vitro fertilization failuresM. Sanmarco, N. Bardin, L. Camoin, G. Porcu (France)

11.55 P105 Prevention of recurrent preeclampsia in patients with genetic thrombophilia and antiphospholipid syndrome A.D. Makatsariya, V.O. Bitsadze, S.V. Akinshina (Russia)

12.05 P125 Can we consider resistance index (RI) value as a new parameter to decide the treatment of connective tissue diseases during pregnancy?F. Bellisai, A. Iuliano, C. Bocchi, L. Congi, C. De Falco, F.M. Severi, M. Galeazzi, F. Petraglia (Italy)

12.15 Discussion




and



19


14.00/16.00 MOTHERS AND BABIES: LONG TERM OUTCOME IN APS SYNDROMEChairmen: F. Falcini (Italy), L. Regan (UK)

14.00 Patients with obstetrical APS onlyA. Parke (USA)

14.10 Children of patients with APSM.C. Boffa, E. Lachassinne (France)

14.20 Neuropsychological development of children of aPL mothersA. Tincani (Italy)

14.30 Discussion

ORAL PRESENTATION SESSIONChairmen: G.R. Cimaz (Italy), McCarty (USA)

14.40 P144 Immunological follow-up of babies born to mothers with APS M.H. Aurousseau, P. Nicaise, E. Lachassinne, C. Boinot, C. Biasini-Rebaioli, S. De Carolis, A. Botta, T. Avcin, M. Motta, L. Carbillon, O. Fain, P. Le Toumelin, S. Besnier, A. Lojacono, M.P. De Carolis, N. Schlegel, S. Derenne, M. Uzan, J. Gaudelus, Y. Laurian, A. Tincani, M.C. Boffa (France, Italy, Slovenia)

14.50 P122 Antiphospholipid syndrome in women with thrombosis and/or adverse pregnancy outcomeB.E. Grand, M.J. Mattioli, L.S. Voto (Argentina)

15.00 P41 Register for pediatric patients with antiphospholipid syndrome: clinical and immunological features of 97 childrenT. Avcin, R. Cimaz, E.D. Silverman, R. Cervera, M. Gattorno, S. Garay, Y. Berkun, F. Sztajnbok, C. Silva, L. Campos, A. Ravelli, A. Martini, B. Rozman, P.L. Meroni (Slovenia, France, Canada, Spain, Italy, Argentina, Israel, Brazil)

15.10 P118 Obstetrical APS: a prospective series of 460 couplesS. Wu, M.D. Stephenson (USA, Canada)

15.20 P120 Brain neurosonography in infants from mothers with positive antiphospholipid antibodies autoimmune diseaseM. Motta, A. Angeli, M.L. Cardone, A. Tincani, A. Lojacono, G. Chirico (Italy)

15.30 Discussion



and


PROGRAM PROGRAM

20


16.15/17.30 TREATING DIFFICULT CASESChairmen: W. Branch (USA), G. Mello (Italy)

16.15 Treatment of pregnant patients not fulfilling the classification criteria W. Ossola (Italy)

16.25 Treatment of pregnant patients with previous thrombosisR.H.W.M. Derksen (The Netherlands)

16.35 Contraception in APS and aPL positive womenC. Laskin (Canada)

16.45 Answers to frequently unanswered questions M.D. Lockshin (USA), A. Tincani (Italy)

16.55 Discussion


and



21

April 20 FridayApril 20 Friday5th INTERNATIONAL CONFERENCE ON SEX HORMONES,

PREGNANCY AND THE RHEUMATIC DISEASES

17.15/18.15 OPENING CEREMONY OF THE V INTERNATIONAL CONFERENCE ON SEX HORMONES, PREGNANCY AND THE RHEUMATIC DISEASES Chairmen: M. Cutolo (Italy), M. Matucci Cerinic (Italy)with the participation of local Authorities

Introductory Lecture by M.D. Lockshin (USA)

18.15/19.00 MATERNAL RHEUMATIC DISEASE AND INFANT HEALTH: NEONATAL LUPUS SYNDROMESChairmen: G.R. Cimaz (Italy), M. Mosca (Italy)

18.15 Pathogenesis R. Clancy (USA)

18.25 Experimental models S. Salomonsson (Sweden)

18.35 Clinical management of in utero diagnosed CHB A. Brucato (Italy)

18.45 Discussion

PROGRAM PROGRAM

22

April 21 SaturdayApril 21 Saturday SCIENTIFIC SCIENTIFIC


8.30/11.00 PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASESChairmen: M. Cutolo (Italy), M.D. Lockshin (USA)

8.30 Systemic lupus erythematosusA. Doria (Italy)

8.40 Rare diseasesM.A. Khamashta (UK)

8.50 SclerodermaM. Matucci Cerinic (Italy)

9.00 EndometriosisS. Ferrero (Italy)

9.10 Autoantibodies and pregnancy lossY. Shoenfeld (Israel)

9.20 Discussion

ORAL PRESENTATION SESSIONChairmen: M. Matucci Cerinic (Italy), M. Khamashta (UK)

9.40 P133 Risk factors of pregnancy in women with pre-pregnancy biopsy proven lupus nephritisA. Tincani, E. Imbasciati, A. Doria, G. Moroni, G. Gregorini, G. Cabiddu, M. Nuzzo, M. Rampudda, F. Valerio, B. Gallelli(Italy)

9.50 P177 Pregnancy outcome in lupus pregnant women with antiphospholopid antibodies F. Mecacci, B. Bianchi, A. Pieralli, R. Cioni, L. Giorgi, C. Buzzoni, A. Mangani, G. Mello (Italy)

10.00 P139 False positive IgM antibody test for cytomegalovirus in pregnant women with autoimmune disease S. De Carolis, A. Botta, S. Santucci, C. Martino, S. Garofalo, G. Fatigante, R. Puccio, A. Alessio, S. Ferrazzani (Italy)

10.10 P140 Human chorionic gonadotropin beta circulating levels in antiphospholipid syndrome affected women during pregnancy: a preliminary case-control studyM. Meroni, P.G. Toniolo, J.M. Dayer (Switzerland, USA)

10.20 P130 Neither healthy pregnants nor pregnants with multiple sclerosis showed serum antibodies against cyclic citrullinated peptidesS. Sánchez-Ramón, D. Oliver-Miñarro, F.J. López-Longo, R. Teijeiro, C. de Andrés, E. Fernández-Cruz, M. Rodríguez-Mahou (Spain)

10.30 Discussion

23

April 21 SaturdayApril 21 Saturday PROGRAM PROGRAM


11.00/11.30 Coffee break and poster viewing11.30/12.30 MECHANISMS OF DISEASE REMISSION IN RHEUMATOID

ARTHRITIS(with the unconditional grant of Wyeth Lederle S.p.A.)Chairmen: M. Montecucco (Italy), M. Østensen (Switzerland)

11.30 Sex hormones as modulators of rheumatoid arthritisM. Cutolo (Italy)

11.40 Factors involved in disease remission of RA during pregnancyM. Østensen (Switzerland)

11.50 Regulatory T cells as modifiers of RA disease activity during pregnancyF. Förger (Germany)

12.00 Pregnancy induced remission and post partum relapse of RA studied by gene microarray analysisP.M. Villiger (Switzerland)

12.10 Discussion


24

April 21 SaturdayApril 21 Saturday


14.00/15.30 ORAL PRESENTATION SESSIONChairmen: R. Abbate (Italy), F. Förger (Germany)

14.00 P136 Angiogenesis and fibrosis evaluation in placenta from systemic sclerosis (SSC) patientL. Ibba-Manneschi, M. Manetti, A.F. Milia, I. Miniati, S. Guiducci, L. Polidori, M. Cinelli, G. Mello, M. Matucci-Cerinic (Italy)

14.10 P131 Preterm deliveries in planned pregnancies of women with systemic lupus erythematosusR. Fischer-Betz, St. Ströhlein, M. Schneider (Germany)

14.20 P129 Sex hormones-linked changes in T-lymphocytes subsets during menstrual cycle and oral contraception may be relevant in autoimmunityR. Teijeiro Martorell, C. Aristimuño, A. Lührmann, C. de Andrés, M. Rodríguez-Mahou, N. López-Lazareno, E. Fernández-Cruz, S. Sánchez-Ramón (Spain)

14.30 P134 Successful pregnancy following hematopoietic stem cell transplantation for severe systemic sclerosisA.J. Tyndall, L. Gilardin, D. Farge (France)

14.40 P113 The occurance of anticardiolipin antibodies and the percentage of B CD19+ and B-1 CD19+5+ lymphocytes in patients with pregnancy complicated by pre-eclampsia and healthy pregnant womenD. Darmochwal-Kolarz, B. Leszczynska-Gorzelak, B. Kolarz, J. Rolinski, J. Oleszczuk (Poland)

14.50 P126 Congenital heart block not associated with anti-SSA/SSBantibodies: a report of 10 casesA. Brucato, C. Grava, M. Bortolati, O. Milanesi, R. Cimaz, M.L. Pisoni, G. Vignati, S. Martinelli, A. Tincani, G. Palmieri, B. Canesi, A. Ruffatti (Italy, France)

15.00 Discussion


25

April 21 SaturdayApril 21 Saturday

15.30/15.45 DRUGS AND PREGNANCY ISponsored by Sanofi Aventis FranceChairmen: M. Cutolo (Italy), S. De Carolis (Italy)

Pregnancy outcomes in women exposed to DMARDs agents: the case of leflunomide C.D. Chambers, K. L. Jones, D.L. JohnsonOTIS Collaborative Research Group


16.15/17.00 DRUGS AND PREGNANCY II(with the unconditional grant of Schering Plough S.p.A.)Chairmen: A Tincani (Italy), A. Parke (USA)

16.15 Anticoagulants and pregnancyR. Abbate (Italy)

16.25 Treating infertility in autoimmune patientsM. Costa (Italy)

16.35 Consensus report on the use of newly introduced antirheumatic drugs in pregnancyM. Østensen (Switzerland)

16.45 Discussion


PROGRAM PROGRAM

26

POSTER SESSIONPOSTER SESSIONPOSTERS TO BE DISPLAYED ON APRIL 18 AND 19, 2007

P1 Beta 2 glycoprotein I dependent antiphospholipid antibodies and myocardial infarction in young pre-menopausalwomen: a multicenter studyP.L. Meroni, A. Tincani, L. Foco, L. Bernardinelli, P.M. Mannucci (Italy)

P2 Cognitive deficits in patients with antiphospholipid syndromeM.G. Tektonidou, N. Varsou, G. Kotoulas, A. Antoniou, H.M. Moutsopoulos (Greece)

P3 Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysisI. Krause, L. Leibovici, M. Blank, Y. Shoenfeld (Israel)

P4 Cross-reactive epitope on β2GPI and saccharomyces cervisiae in patients with the antiphospholipid syndromeI. Krause, M. Blank, R. Cervera, J. Font, T. Matthias, A. Fraser, Y. Shoenfeld (Israel, Spain, Germany)

P5 Anti-cardiolipin: a pro-thrombotic and pro-atherogenic autoantibodyY. Sherer, Y. Shoenfeld (Israel)

P6 Anti-glycans antibodies in the sera of antiphosopholipid syndromeM. Blank, L. Anafi, N. Dotan, A. Dukler, Y. Shoenfeld (Israel)

P7 Pathophysiological mechanisms of vasculopathy in systemic scleroderma (SSc): platelet activation induced by aPL is associated with arterial thromboses and digital pitting scar in SSc patientsM. Yamazaki, Y. Kadohira, Y. Ontachi, H. Asakura, S. Nakao (Japan)

P8 Abdominal and digestive manifestations in antiphospholipid syndrome: the current evidence for its managementS. Hammami, W. Kallel, F. Bdioui, A. Barhoumi, A. Hamzaoui, A. Hamdi, H. Safar, S. Mahjoub (Tunisia)

P9 Antiphospholipid syndrome: cohort of Tunisian patients with systemic lupus erythematosusS. Hammami, W. Chebbi, S. Aloui, R. Boumiza, A. Hamzaoui, M. Hassine, M. El May, S. Mahjoub (Tunisia)

P10 Factor XIII Val34Leu polymorphism is associated to the risk of thrombosis in patients with antiphospholipid antibodies and high fibrinogen levelsG. de la Red, G. Espinosa, D. Tàssies, A. Bové, J.C. Reverter, R. Cervera (Spain)

P11 Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations and evolutionI. Moyssakis, M.G. Tektonidou, V.A. Vasilliou, M. Samarkos, H.M. Moutsopoulos (Greece)

P12 Clinical and serological 5 years follow of 100 patients with anticardiolipin antibodiesI. Asher, A. Levinson, D. Elbirt, D. Sthoeger, Z. Sthoeger (Israel)

P13 Transiently positive anticardiolipin antibodies do not increase the risk of thrombosis in patients with systemic lupus erythematosusA. Martinez-Berriotxoa, G. Ruiz-Irastorza, M.V. Egurbide, M. Garmendia, J.G. Erdozain, I. Villar, C. Aguirre (Spain)

P14 Secondary thromboprophylaxis in antiphospholipid syndrome: a systematic reviewG. Ruiz-Irastorza, B.J. Hunt, M.A. Khamashta (Spain, UK)

P15 Lupus anticoagulant: a two years experience with four testsD. Cosseddu, C. Marchese, M.T. Bertero, S. Sciascia, N. Renzi, G.C. Molinaro (Italy)

P16 Specific binding of antiphospholipid antibodies to defined white matter tracts in a mouse modelA. Katzav, I. Eshcoli, M. Blank, Y. Shoenfeld, J. Chapman (Israel)

P17 Trousseau's syndrome in course of neoplastic diseaseD. Samulak, R. Moszynski, J. Buks, M. Pisarska, S. Sajdak (Poland)

P18 The clinical significance of Hughes' syndrome in diagnostics of thromboembolism complications in a group of patients suffering from malignant genital organs' cancerD. Samulak, M. Pisarska, J. Buks, P. Uchman, S. Sajdak (Poland)

P19 High avidity anticardiolipin antibodies in patients with haematological malignanciesS. Andrejevic, B. Bonaci-Nikolic, M. Sefik-Bukilica (Serbia)

P20 Factor V Leiden and prothrombin gene mutation are not associated with thrombosis in patients with antiphospholipid syndromeG. Espinosa, G. Claver, D. Tassies, J. Plaza, J.C. Reverter, R. Cervera (Spain)

P21 Relapsing catastrophic antiphospholipid syndromeS. Bucciarelli, G. Espinosa, S. Menahem, J. Yinh, R. Cervera, R.A. Asherson (Spain, Australia, USA, South Africa)

P22 The role of malignancies in patients with catastrophic antiphospholipid (Asherson's) syndromeW. Miesbach, R.A. Asherson, R. Cervera, Y. Shoenfeld, J. Gomez Puerta, G. Espinosa, S. Bucciarelli and the members of the CAPS Registry Group (Germany, South Africa, Spain, Israel)

P23 Is age a risk factor for the manifestation of the antiphospholipid syndrome?W. Miesbach, R. Hudek, G. Asmelash, B. Lugalio, I. Scharrer, R. Grossmann (Germany)

P24 Patients with primary antiphospholipid syndrome present a normal endothelial function (EF)P. Gresele, R. Migliacci, C. Vedovati, C. Becattini, G. Guglielmini, A.M. Mezzasoma, C. Pegoraro, A. Cavazzana, A. Calligaro, A. Ruffatti, V. Pengo (Italy)

P25 Survey on lupus anticoagulant (LA) diagnosis in ItalyV. Pengo, A. Biasiolo, A. Ruffatti, P. Gresele, F. Marongiu, N. Erba, F. Veschi, A. Ghirarduzzi, E. De Candia, B. Montaruli, S. Testa, D. Barcellona, A. Tripodi (Italy)

P26 Primary antiphospholipid syndrome patients consume more weekly warfarin than inherited thrombophilia patients at similar target INRP.R.J. Ames, A. Ciampa, G. Scenna, L. Iannaccone, M. Margaglione, V. Brancaccio (UK, Italy)

P27 Atherosclerosis in primary antiphospholipid syndromeP.R.J. Ames, A. Margarita, L. Lopez, E. Matsuura, L. Antinolfi, G. Scenna (UK, Italy, USA, Japan)

P28 C-reactive protein in primary antiphospholipid syndromeP.R.J. Ames, A. Ciampa, G. Scenna, L. Antinolfi, L. Lopez, E. Matsuura (UK, Italy, USA, Japan)

27

POSTERS TO BE DISPLAYED ON APRIL 18 AND 19, 2007

P29 Ocular manifestations in antiphospholipid syndromeL.J. Stojanovich, G. Suvajac, S. Milenkovich (Serbia)

P30 Not to be presented

P31 Association between primary antiphospholipid syndrome and angiosarcoma of the faceV. Salle, A. Smail, M. Mahevas, J. Desblache, S. Testelin, B. Devauchelle, C. d'Hauthuille, R. Cevallos, P. Duhaut, J.P. Ducroix (France)

P32 Premature atherosclerosis and cardiovascular events (CVE) in patients with systemic lupus erythematosus (SLE)with or without antiphospholipid syndrome (APS) and lupus nephritis (LN)N.L. Kozlovskaya, S.Y. Serikova, E.M. Shilov (Russia)

P33 The role of angiography in nontrombogenic manifestations of occlusive blood vessels disease diagnosticsJ. Saponjski, Lj. Stojanovic, N. Ilijevski, M. Krotin, M. Stanisic (Serbia)

P34 Primary antiphospholipid syndrome - A serie of 29 patientsC. Costa, A. Ribeiro, L. Sampaio, C. Carvalho, R. Castanheira, F. Coelho, C. Dias (Portugal)

P35 Antiphospholipid antibodies in a tertiary hospital in Spain: influence of the age, sex, and underlying condition on their clinical expressionJ.M. Pego-Reigosa, S. Gómez-Isorna, F. González-Carril, D. Táboas, I. García-Bernal, C. Gómez-Bezares, I. Hernández, A. Fernández-Nogueira, L. Enríquez, R. Pérez-Álvarez (Spain)

P36 Flow mediated vasodilation. A diagnostic instrument to evaluate endothelial dysfunction in patient with antiphospholipid antibodiesA. Dumitrascu, C. Tanaseanu, I. Tamsula, G. Orosan, G. Gheorghe (Romania)

P37 Importance of APLA in pathogenesis of thrombotic events associated with bacterial respiratory tract infectionsC. Tanaseanu, S. Tanaseanu, A. Dumitrascu, I. Tamsula, M. Popescu (Romania)

P38 Antiphospholipid antibodies in systemic sclerosisSt. Tanaseanu, C. Tanaseanu, I. Tamsula, A. Dumitrascu, M. Popescu (Romania)

P39 Antiphospholipid syndrome - 4 severe case reportsA. Ribeiro, C. Costa, C. Dias (Portugal)

P40 Longitudinal follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosusT. Avcin, S.M. Benseler, P.N. Tyrrell, S. Cucnik, E.D. Silverman (Canada, Slovenia)

P41 Register for pediatric patients with antiphospholipid syndrome: clinical and immunological features of 97 childrenT. Avcin, R. Cimaz, E.D. Silverman, R. Cervera, M. Gattorno, S. Garay, Y. Berkun, F. Sztajnbok, C. Silva, L. Campos, A. Ravelli, A. Martini, B. Rozman, P.L. Meroni(Slovenia, France, Canada, Spain, Italy, Argentina, Israel, Brazil)

P42 APLASA - A randomized, double-blind, placebo-controlled primary thrombosis prevention trial in asymptomatic aPL-positive individuals with aspirinD. Erkan, M.J. Harrison, R. Levy, M. Peterson, M. Petri, L. Sammaritano, A. Unalp-Arida, V. Vilela, Y. Yazici, M.D. Lockshin (USA, Brazil)

P43 Precipitating factors in catastrophic antiphospholipid syndromeU.D. Bayraktar, D. Erkan, S. Bucciarelli, G. Espinosa, R. Cervera, R. Asherson (USA, Spain, South Africa)

P44 Catastrophic antiphospholipid syndrome (CAPS): comparison between CAPS patients with and without thrombocytopeniaU.D. Bayraktar, D. Erkan, S. Bucciarelli, G. Espinosa, R. Cervera, R. Asherson (USA, Spain, South Africa)

P45 Antiphospholipid antibody (aPL) tests and aPL-related clinical events: is there a seasonal variation?N. Kutlu, D. Erkan, M. Varley, L. Sammaritano, S. Pierangeli, R. Roubey, M.D. Lockshin (Turkey, USA)

P46 Executive and visual-motor dysfunction in pediatric lupusE. Muscal, D.R. Bloom, B.L. Myones (USA)

P47 Antiphospholipid antibody testing in Piemonte and Valle d'Aosta: a multilaboratory external quality assurance (EQA) programB. Montaruli, A. Vaccarino, G. Mengozzi, M. Saitta, M. Bazzan (Italy)


P49 High digestive haemorrhage by oesophageal varices DEGREE 0-1 of Paquet secondary to presinuosity portal hypertension due to portal vein thrombosis with development of cavernomatosis in a young woman how first manifestation of primary antiphospholipid antibody syndromeM.R. Rodríguez Moreno, M. Guzmán Úbeda, R. Cáliz Cáliz, J. Jimenez Alonso, R. Martin-Vivaldi Martinez,I. Rodríguez Moreno (Spain)

P50 CD45 exon 6 A138G polymorphism is associated with antiphospholipid syndromeT. Horita, H. Nakagawa, Y. Sakai, H. Kataoka, S. Yasuda, T. Atsumi, T. Koike (Japan)

P51 Antiphospholipid antibodies in lupus nephritis. A clinical and pathological studyV. Savio, P. Alba, C. Gobbi, M. Herrero, S. Amione, G. Ghirardi, A. Babini, I. Exeni, E. Albiero (Argentina)

P52 Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type offluid replacementT. Tison, P. Bagatella, M. Ciprian, A. Ruffatti, G. Luzzatto, F. Fabris, P. Marson, G. De Silvestro (Italy)

P53 Autoimmune hepatitis and antiphospholipid syndrome: a case reportC. Costa, A. Ribeiro, C. Dias (Portugal)

P54 Primary antiphospholipid syndrome - A series of 29 patientsC. Costa, A. Ribeiro, L. Sampaio, C. Carvalho, R. Castanheira, F. Coelho, C. Dias (Portugal)

POSTER SESSIONPOSTER SESSION


P55 Outcome of kidney transplantation in a patient with primary antiphospholipid syndromeM. Ciprian, P. Marson, M. Tonello, T. Del Ross, C. Grava, E. Cozzi, P. Rigotti, A. Ruffatti (Italy)

P56 Antiphospholipid (aPL) syndrome and infection riskR. Bergia, A. Kuzenko, S. Sciascia, D. Gottardi, M. Fracchia, M.T. Bertero (Italy)

P57 Increased incidence of IgG and IgM autoantibodies to phospholipids in primary versus secondary antiphospholipid syndromeR.H. Budd, G.E. Harley, D.J. Taylor, D. Isenberg, A.R. Bradwell (UK)

P58 Secondary antiphospholipid syndrome (APS) in a cohort of Greek patients with systemic lupus erythematosus (SLE)N.G. Papadopoulos, G. Tsiaousis, A. Giannakou, A. Pavlitou-Tsiontsi, V. Galanopoulou (Greece)

P59 Antiphospholipid antibodies and neuro-vasculo-BehçetV. Calabrese, A. Marchetti, L. Pettinari, M. Permon, M.G. Danieli (Italy)

P60 Interstitial lung disease in systemic lupus erythematosus and antiphospholipid syndromeL. Pettinari, L. Calcabrini, A. Marchetti, L. Limiti, C. Massaccesi, M.G. Danieli (Italy)

P61 Livedoid vasculitis and multiple mononeuropathy in a patient with catastrophic antiphospholipid syndromeA. Marchetti, L. Calcabrini, V. Calabrese, M. Sediari, F. Logullo, M.G. Danieli (Italy)

P62 Characterization and study of congenital deficiency of proteins C and S associated with systemic lupus erythematosus, secondary antiphospholipid antibody syndrome and monoclonal gammopathy of undetermined significanceM.R. Rodríguez Moreno, M. Guzmán Úbeda, J. Jimemez Alonso, R. Cáliz Cáliz, M.J. Gutiérrez Pimentel, L. Rodríguez Moreno (Spain)

P63 Cerebral venous thrombosis in a child with antiphospholipid syndrome and genetic thrombophiliasA. Vitale, F. La Torre, R. Gallizzi, C. Fede, G. Calcagno (Italy)

P64 Behçet's disease and positive antiphospholipid antibodies: what are the consequences?A. Barhoumi, S. Hammami, A. Hamzaoui, S. Mahjoub (Tunisia)

P65 Study of anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patient with ischemic strokeA. Astrinidou-Vakaloudi, P. Papastergiou, E. Nanousi, V. Papakostantinou, B. Galanopoulou (Greece)

P66 Systematic detection of antiphospholipid antibodies in neurological patientsA. Turcu, S. Audia, G.-V. Oseby, M. Giroud, J.-F. Besancenot (France)

P67 Effect of rosuvastatin on vascular cell adhesion molecule 1 (VCAM-1) expression by human endothelial cells exposed to antiphospholipid syndrome serum in an in vitro modelL.A. Martínez-Martínez, M.C. Amigo, A. Orozco, M. Núñez, O. Nuevo, I. Rodríguez, G. Medina, G. Ceballos, L.J. Jara (Mexico)

P68 Successful cardiac valve replacement in two patients with APS who received preoperatively plasma exchange plus IVIGM.C. Amigo, R. Izaguirre, L. Amezcua-Guerra, E. Cortina, F. Santibáñez (Mexico)


P70 Antiphospholipid antibody (aPL) reduction in patients treated with low dose aspirin (LDA) & hydroxychloroquine (HCQ): recursive partitioning analysis of a large antiphospholipid syndrome cohortG.A. McCarty, T.E. Cason (USA)

P71 Significance of plasma soluble endothelial protein C receptor in antiphospholipid syndromeD. Wahl, C. Perret-Guillaume, P. Kaminsky, P. Lacolley, V. Regnault, T. Lecompte (France)

P72 The risk of heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: a meta-analysis of echocardiographic studiesP. Dotto, C. Perret-Guillaume, E. Bode, E. De Maistre, J.F. Bruntz, V. Regnault, T. Lecompte, D. Wahl (France)

P73 Plasma protein Z and antiphospholipid syndromeD. Wahl, C. Perret-Guillaume, P. Kaminsky, P. Lacolley, T. Lecompte, V. Regnault (France)

P74 Aspects of retinal vessels associated with APS antibodies present used in thrombosis preventionT. Rosca (Romania)

P75 Cardiac valve replacement in APS patientsJ.G. Erdozain, M.V. Egurbide, M.C. Amigo, M.I. Segura, G. Espinosa, J.L. Pomar, I. Perez, M.A. Khamastha (Spain, UK, Mexico)

P76 Pilot study of a USB drive personal health record (PHR) for systemic lupus erythematosus (SLE) & antiphospholipid antibody syndrome (APS) patient empowerment & care quality improvementG.A. McCarty, T.E. Cason (USA)

P77 Anticardiolipin antibodies in young patients with myocardial infarctionN. Antonijevic, S. Andrejevic, B. Bonaci, A. Beletic, Z. Jovicic, J. Perunicic, M. Bukelica, D. Jovanovic, B. Jakovljevic, N. Majkic Singh, Z. Vasiljevic (Serbia)

P78 Evaluation of several ELISA tests used in the diagnosis of antiphospholipid syndrome in a large cohort of patientsamplesS.S. Pierangeli, V. Henderson, E. Papalardo, J. Rice, P. Padilla, M.O. Borghi, F. Pregnolato, P.L. Meroni, R.L. Brey, A. Quarshie, D.W. Branch (USA, Italy)

P79 The use of "screening" tests for lupus anticoagulant in active vasculitic diseases such as systemic lupus may lead to false negative resultsB.L. Myones, E. Muscal, A.G. West, R.M. Edwards, J. Teruya (USA)

P80 Annexin A5 in cardiovascular disease and antiphospholipid syndrome: a novel mechanismA. Cederholm, J. Su, P. Von Landenberg, J. Frostegard (Germany)

28


29


P81 Diagnostic approach to bilateral chorea associated with osteonecrosis in a patient antiphospholipid antibodies positiveA. Kuzenko, R. Bergia, S. Sciascia, L. Sosso, A. Bonzano, M. Germano, S. Martino, C. Defilippi, A. Linari, M.T. Bertero (Italy)

P82 The hemorrhagic lupus anticoagulant syndromeP. Sabatini, P. Danise, L. Clemente, A. Tedesco, C. Esposito, G. Rescigno, G. Amendola (Italy)

P83 The risk of thrombosis in patients with lupus anticoagulantI. Kalidi, T. Bibi Triki, D. Bengoufa, R. Porcher, L. Dubertret, P. Morel, E. Oksenhendler, L. Galicier, M.L. Scrobohaci (France)

P84 Seizure in a patient with systemic lupus erythematosus (SLE): a case reportS. Cozzolino, A. Locatelli, M. Incerti, S. Consonni, M.R. Pozzi (Italy)

P85 Phosphatidylserine-dependent anti-prothrombin antibody-IgM is associated with livedo reticulopathyM. Yamazaki, Y. Kadohira, M. Maekawa, Y. Ontachi, H. Asakura, S. Nakao (Japan)

P86 Pediatric APS and recurrent thrombosisY. Berkun, S. Padeh, J. Barash, Y. Uziel, L. Harel, M. Mukamel, S. Revel-Vilk, G. Kenet (Israel)

P87 Antiphospholipid antibody syndrome (APS): the annexin V competition assay as a diagnostic toolA. Tomer, S. Bar-Lev, S. Fleisher, B. Shenkman, M. Friger, M. Abu-Shakra (Israel)

P88 Anticardiolipin antibodies as thrombosis risk factors in the treated patients with antiphospholipidA. Haroyan, N. Mkrtchyan, K. Tokhunts, T. Galstyan (Armenia)

P89 Antiphospholipid syndrome. The significance of the determination of antibodies to phospholipidsM.P. Baleva, K.V. Nikolov, M.K. Nikolova (Bulgaria)

P90 Changes in the humoral immune response in patients with Henoch-Schönlein vasculitisK.V. Nikolov, Pl. Jakovliev, M.P. Baleva, N. Dobreva, M.K. Nikolova (Bulgaria)

P91 Cardiolipin autoantibodies in chronically HIV infected patientsV. Martinez, M. Diemert, J. Charuel, E. Caumes, C. Katlama, B. Autran, L. Musset and the ALT StudyGroup (France)

P92 Incidence of isolated increases of anti-prothrombin antibodies and anti-phosphatidylserine antibodies in patientssuspected of having phospholipid antibodies (aPL)R.C. Gosselin, K.A. Janatpour, J.T. Owings (USA)

P93 Evaluation of thrombin generation in patients with lupus anticoagulantJ. Serratrice, C. Sanchez, P. Morange, M.C. Alessi, P. Disdier, I. Juhan, P.J. Weiller (France)

P94 Occurrence of anti-phospholipid antibodies in 399 patients with rheumatoid arthritis treated with three differentanti-tumour necrosis alpha agentsF. Atzeni, A. Doria, M. Antivalle, M. Turiel, M. Carrabba, P. Sarzi-Puttini (Italy)

P95 Anti-prothrombin/phosphatidylserine antibodies: another member of the APLs familyC. Anzilotti, G. Longombardo, A. Perrella, P. Migliorini (Italy)

P96 Autoimmunity in the cancerI. Bernardini, L. Pugliese, M. Viola Magni, E. Albi (Italy)

P97 Antinucleosome antibodies in primary antiphospholipid syndromeL. Andreoli, F. Pregnolato, R. Burlingame, V. Fanelli, F. Allegri, A. Radice, A. Sinico, A. Tincani, P.L. Meroni (Italy, USA)

P98 Multiple infectious agents screen in antiphospholipid syndromeY. Sherer, O. Barzilai, M. Blank, B. Larida, Y. Shoenfeld (Israel, USA)

P99 Multiple antiphospholipid autoantibody screen in systemic lupus erythematosusY. Sherer, O. Barzilai, J.M. Anaya, M. Blank, B. Larida, Y. Shoenfeld (Israel, Colombia, USA)

P100 Multiple infectious agents screen in systemic lupus erythematosusO. Barzilai, Y. Sherer, J.M. Anaya, M. Blank, B. Larida, Y. Shoenfeld (Israel, Colombia, USA)

P101 Antiphospholipid antibodies and central nervous system involvement: direct autoantibody binding to neuronal cellsT. Lavazza, A. Dipinto, M.O. Borghi, V. Usuelli, A. Bergamaschi, V. Zimarino, P.P. Chen, P.L. Meroni, A. Malgaroli (Italy, USA)

P102 First thrombotic event in patients with obstetric APSM. Nuzzo, A. Ceribelli, F. Allegri, G. Gorla, G. Balestrieri, R. Cattaneo, A. Tincani (Italy)


P103 Pro-inflammatory genotype as a risk factor for APS clinical manifestations: a case reportV. De Angelis, E. Raschi, R. Cimaz, S. Scurati, M. Bigioggero, M.O. Borghi, P.L. Meroni (Italy, France)

P104 Third-trimester fetal death associated to antiphospholipid syndrome and/or inherited thrombophilia: results of subsequent pregnancies with adjusted dose enoxaparin treatment plus aspirinC. Pappalardo, A. Sarto, M. Martínez, A. Falco, L. Mezzabotta, R.S. Pasqualini (Argentina)

P105 Prevention of recurrent preeclampsia in patients with genetic thrombophilia and antiphospholipid syndromeA.D. Makatsariya, V.O. Bitsadze, S.V. Akinshina (Russia)

P106 Antiphospholipid antibodies in women with history of recurrent fetal loss and their childrenA.D. Makatsariya, S.M. Baimuradova, V.O. Bitsadze, S.V. Akinshina (Russia)

P107 New damage mechanisms of antiphospholipid antibodies on trophoblast cells: inhibition of HB-EGF expressionN. Di Simone, S. D'Ippolito, P.L. Meroni, M.C. D'Alessio, F. Di Nicuolo, R. Castellani, A. Caruso (Italy)

P108 Combined estrogen / progestin therapy's influence of vascular system and lipid profile occuring in menopausal ageD. Samulak, M. Pisarska, J. Buks, R. Moszynski, S. Sajdak (Poland)



P109 Complement as a predictor of miscarriageM. Sugiura-Ogasawara, Y. Ozaki, T. Nakanishi, K. Nozawa, K. Aoki (Japan)

P110 Pregnancy outcome in women with systemic lupus erythematosusA. Barcelos, J. Santos, S. Capela, R. Figueira, P. Nero, A. Alves de Matos, C. Silva, L. Miranda, A. Teixeira, J. Branco, J. Canas da Silva, M. Viana de Queiroz (Portugal)

P111 Applied protocol with group control for therapeutic clinical follow-up of antiphospholipid syndrome (APS) duringpregnancyJ.O. Latino, D. Fernandez Romero, G. Bierfass, C. Becker, J.C. Nassif, C. Allami, J.J. Scali (Argentina)

P112 The antiphospholipid syndrome, metabolic syndrome, inherited forms of thrombophilia and pregnancyA.D. Makatsaria, E.B. Perederyaeva, T.B. Pshenichnikova (Russia)

P113 The occurance of anticardiolipin antibodies and the percentage of B CD19+ and B-1 CD19+5+ lymphocytes in patients with pregnancy complicated by pre-eclampsia and healthy pregnant womenD. Darmochwal-Kolarz, B. Leszczynska-Gorzelak, B. Kolarz, J. Rolinski, J. Oleszczuk (Poland)

P114 Apheresis in high risk pregnancies of women with antiphospholipid syndrome. Immunoadsorption or plasma exchange? Two case reportsM. Bortolati, P. Marson, T. Tison, M. Favaro, R. Ponchia, D. Truscia, G. De Silvestro, A. Ruffatti (Italy)

P115 Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 casesA. Ruffatti, P. Marson, V. Pengo, M. Favaro, M. Tonello, M. Bortolati, D. Minucci, G. De Silvestro (Italy)

P116 Antiphospholipid syndrome (APS) based on a history of recurrent miscarriage (APS/RM): the importance of cytogenetic analysisM.D. Stephenson, S. Wu (Canada, USA)

P117 Successful outcome in 67 APS pregnancies treated with coumadinN.R. Jesús, R.A. Levy, G.R.R. Jesús, V.S. Vilela, A.M.H. Lima, E.M.N. Albuquerque (Brazil)

P118 Obstetrical APS: a prospective series of 460 couplesS. Wu, M.D. Stephenson (USA, Canada)

P119 Primary antiphospholipid syndrome: clinical and biological characteristics of 40 casesM. Khalifa, N. Gannouchi, N. Kaabia, S. Hadj Khalifa, K. Baccouche, E. Benjazia, A. Krifa, A. Letaief, F. Bahri (Tunisia)

P120 Brain neurosonography in infants from mothers with positive antiphospholipid antibodies autoimmune diseaseM. Motta, A. Angeli, M.L. Cardone, A. Tincani, A. Lojacono, G. Chirico (Italy)

P121 Placental thrombosis and repeated late fetal loss: a diagnostic and therapeutic challengeA. Maina, V. Donvito, L. Marozio, B. Montaruli (Italy)

P122 Antiphospholipid syndrome in women with thrombosis and/or adverse pregnancy outcomeB.E. Grand, M.J. Mattioli, L.S. Voto (Argentina)

P123 Perinatal outcome in women with antiphospholipid syndromeL.S. Voto, M.J. Mattioli, B.E. Grand (Argentina)

P124 Pregnancy and antiphospholipid syndromeA. Barhoumi, A. Hamzaoui, S. Hammami, S. Mahjoub (Tunisia)

P125 Can we consider Resistance Index (RI) value as a new parameter to decide the treatment of connective tissue diseases during pregnancy?F. Bellisai, A. Iuliano, C. Bocchi, L. Congi, C. De Falco, F.M. Severi, M. Galeazzi, F. Petraglia (Italy)

P126 Congenital heart block not associated with anti-SSA/SSB antibodies: a report of 10 casesA. Brucato, C. Grava, M. Bortolati, O. Milanesi, R. Cimaz, M.L. Pisoni, G. Vignati, S. Martinelli, A. Tincani, G. Palmieri, B. Canesi, A. Ruffatti (Italy, France)

P127 Case report: successful pregnancy during CNS lupus and pulse cyclophosphamide treatmentD. Palic-Obradovic, R. Stojanovic, M. Cvetkovic (Serbia)

P128 Primary antiphospholipid syndrome in pregnancy: maternal and foetal outcomeP. Alba, C. Palena, A. Alvarez, M. De Marchi, V. Pedano, F. Crespo (Argentina)

P129 Sex hormones-linked changes in T-lymphocytes subsets during menstrual cycle and oral contraception may be relevant in autoimmunityR. Teijeiro Martorell, C. Aristimuño, A. Lührmann, C. de Andrés, M. Rodríguez-Mahou, N. López-Lazareno, E. Fernández-Cruz, S. Sánchez-Ramón (Spain)

P130 Neither healthy pregnants nor pregnants with multiple sclerosis showed serum antibodies against cyclic citrullinated peptidesS. Sánchez-Ramón, D. Oliver-Miñarro, F.J. López-Longo, R. Teijeiro, C. de Andrés, E. Fernández-Cruz, M. Rodríguez-Mahou (Spain)

P131 Preterm deliveries in planned pregnancies of women with systemic lupus erythematosusR. Fischer-Betz, St. Ströhlein, M. Schneider (Germany)

P132 Pregnancy outcome in patients with systemic vasculitisH.S. Koksvik, B. Jakobsen, A. Dhainaut, J.F. Skomsvoll (Norway)

P133 Risk factors of pregnancy in women with pre-pregnancy biopsy proven lupus nephritisA. Tincani, E. Imbasciati, A. Doria, G. Moroni, G. Gregorini, G. Cabiddu, M. Nuzzo, M. Rampudda, F.Valerio, B. Gallelli (Italy)

P134 Successful pregnancy following hematopoietic stem cell transplantation for severe systemic sclerosisA.J. Tyndall, L. Gilardin, D. Farge (France)

P135 Dilated cardiomyopathy in child with antibodies antiSSA/RO positive motherB. Berluti, A.L. Tranquilli, M.G. Danieli, A. Marchetti (Italy)

30



P136 Angiogenesis and fibrosis evaluation in placenta from systemic sclerosis (SSC) patientL. Ibba-Manneschi, M. Manetti, A.F. Milia, I. Miniati, S. Guiducci, L. Polidori, M. Cinelli, G. Mello, M. Matucci-Cerinic (Italy)

P137 The role of maternal and neonatal APLA in perinatal strokeM.J. Simchen, G. Goldstein, A. Lubetsky, I. Tamarin, M. Dulitzki, E. Schiff, G. Kenet (Israel)

P138 Applied protocol with group control for therapeutic clinical follow-up of antiphospholipid syndrome (APS) duringpregnancyJ.O. Latino, D. Fernandez Romero, G. Bierfass, C. Becker, J.C. Nassif, C. Allami, J.J. Scali (Argentina)

P139 False positive IgM antibody test for cytomegalovirus in pregnant women with autoimmune diseaseS. De Carolis, A. Botta, S. Santucci, C. Martino, S. Garofalo, G Fatigante, R. Puccio, A. Alessio, S. Ferrazzani (Italy)

P140 Human chorionic gonadotropin beta circulating levels in antiphospholipid syndrome affected women during pregnancy: a preliminary case-control studyM. Meroni, P.G. Toniolo, J.M. Dayer (Switzerland, USA)

P141 Successful management of late obstetric complications in the antiphospholipid syndromeS.K. Austin, M.J. Nash, D. Peebles, H. Cohen (UK)

P142 The prognostic significance of ultrasound placentometry at the early periods of pregnancy in women with APSK. Tokhunts, A. Haroyan, N. Shahverdyan (Armenia)

P143 Clinical follow-up of babies born to mothers with APSE. Lachassinne, M. Motta, M.P. De Carolis, S. Besnier, T. Avcin, M.H. Aurousseau, L. Carbillon, O. Fain, P. Nicaise, P. Le Toumelin, C. Biasini-Rebaioli, A. Lojacono, S. De Carolis, A. Botta, C. Boinot, S. Derenne, N. Schlegel, A. Tincani, M. Uzan, Y. Laurian, J. Gaudelus, M.C. Boffa(France, Italy, Slovenia)

P144 Immunological follow-up of babies born to mothers with APSM.H. Aurousseau, P. Nicaise, E. Lachassinne, C. Boinot, C. Biasini-Rebaioli, S. De Carolis, A. Botta, T. Avcin, M. Motta, L. Carbillon, O. Fain, P. Le Toumelin, S. Besnier, A. Lojacono, M.P. De Carolis, N. Schlegel, S. Derenne, M. Uzan, J. Gaudelus, Y. Laurian, A. Tincani, M.C. Boffa(France, Italy, Slovenia)

P145 Pregnancy in systemic erythematosus lupus: clinical and therapeutic implications. Case reportC. Ancuta, E. Ancuta (Romania)

P146 Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressantsM. Biggioggero, M.O. Borghi, M. Gerosa, L. Trespidia, R. Cimazb, P.L. Meroni (Italy)

P147 Effects of a toll-like receptor antagonist and anti-annexin A2 antibodies on binding and activation of decidual cells by anti-β2-glycoprotein I antibodiesM.O. Borghi, E. Raschi, S. Scurati, C. Grossi, S.S. Pierangeli, P.L. Meroni (Italy, USA)

P148 Protection against inflammation - and antiphospholipid antibody - caused fetal loss by the chemokine decoy receptor D6Y. Martinez de la Torre, C. Buracchi, E.M. Borroni, J. Dupor, R. Bonecchi, M. Nebuloni, F. Pasqualini, A. Doni, E. Lauri, C. Agostinis, R. Bulla, D.N. Cook, B. Haribabu, P.L. Meroni, D. Rukavina, L. Vago, F. Tedesco, A. Vecchi, S.A. Lira, M. Locati, A. Mantovani (Italy, USA, Croazia)

P149 Antiphospholipid antibodies testing: towards automatisationL. Andreoli, L. Pallavicini, F. Capuano, S. Rizzini, A. Tincani (Italy)

P150 Innate immune signal in new murine models of autoimmunity induced by U1 RNA and the RNA binding domainof the U1-70kD ribonucleoprotein antigenA. Avril, E.L. Greidinger, K. Jaimes, Y. Zang, R.W. Hoffman (USA)

P151 Transgelin, anti-transgelin antibodies and kidney involvement in antiphospholipid syndromeM. Blank, P.L. Meroni, R. Cervera, J. Font, J. Kopilovic, C. Avivi, Y. Shoenfeld (Israel, Spain, Italy)

P152 Comparing anti-phospholipids antibodies in normal donors and thromboembolic patients using multiplex technologyR.C. Gosselin, K.A. Janatpour, J.T. Owings (USA)

P153 Evaluation of multiplex technology for measuring anti-phospholipid antibodiesR.C. Gosselin, K.A. Janatpour, J.T. Owings (USA)

P154 Expression and regulation of protease-activated receptors (PARs) in monocytes from patients with APSM.J. Cuadrado, P. Buendía, M.A. Aguirre, N. Barbarroja, A. Torres, F. Velasco, M.A. Khamashta, C.H. Lopez-Pedrera (UK, Spain)

P155 Proteomic analysis of purified monocytes from patients with antiphospholipid syndromeM.J. Cuadrado, P. Buendía, M.A. Aguirre, N. Barbarroja, A. Torres, M.A. Khamashta, F. Velasco, Ch. Lopez-Pedrera (UK, Spain)

P156 Differences in antigen binding of high and low avidity anti-beta2-glycoprotein I antibodiesS. Cucnik, T. Kveder, B. Rozman, B. BoΩic (Slovenia)

P157 Changes in specificity of common IgG during electrooxidationB. BoΩic, S. Cucnik, T. Kveder, B. Rozman (Slovenia)

P158 Anti-ß2-glycoprotein I antibodies in complex with ß2-glycoprotein I can activate platelets via glycoprotein Ib-IX-VB. Giannakopoulos, T. Shi, X. Yan, P. Yu, M.C. Berndt, R.K. Andrews, J. Rivera, G.M. Iverson, K.A. Cockerill, M.D. Linnik, S.A. Krilis (Australia, USA)

P159 Signaling via both GPIba and ApoER2' is required for platelet activation by dimeric ß2-glycoprotein IR.T. Urbanus, M.T.T. Pennings, R.H.W.M. Derksen, P.G. de Groot (The Netherlands)

P160 Phosphatidylserine dependent antiprothrombin antibody induces p38 mitogen-activated protein kinase (MAPK) phosphorylation leading to tissue factor expressionK.Oku, T. Atsumi, O. Amengual, H. Kataoka, T. Horita, S. Yasuda, T. Koike (Japan)

31



P161 Detection of anti-ß2-glycoprotein I antibodies: comparison of the results obtained with different antigen preparationsA. Cavazzana, V. Pengo, M. Tonello, F. Noventa, M.O. Borghi, C. Grossi, P.L. Meroni, G. Reber, A. Ruffatti (Italy, Switzerland)

P162 Antagonist effect of antiphospholipid antibodies and ß-2 glycoprotein I on budding phospholipid vesiclesM. Lokar, M. Frank, S. Cucnik, J. Urbanija, A. Iglic, V. Kralj-Iglic, B. Rozman (Slovenia)

P163 ACTICLOT® dPT Dilute Prothrombin Time Test can increase detection of lupus anticoagulants in routine clinical testingE. Guinto, C. Santulli, R.S. Greenfield (USA)

P164 Practicability of the triturus enzyme immunoassay autoanalyzer of GrifolsM.R. Rodríguez Moreno, M.J. Gutiérrez Pimentel, M. Lozano, L. Rodríguez Moreno (Spain)

P165 Evaluation of the triturus enzyme immunoassay autoanalyzer for the measurement of 2-glycoprotein IM.R. Rodríguez Moreno, M.T. Miranda, M.J. Gutiérrez, M. Lozano, L. Rodríguez Moreno (Spain)

P166 C5a receptor deficient mice are protected from thrombophilia and endothelial cell activation induced by IgM antiphospholipid antibodiesZ. Romay-Penabad, X. Liu, S.S. Pierangeli (USA)

P167 Role of p38 mitogen activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelialcell activationM.E. Vega-Ostertag, Z. Romay-Penabad, D.E. Ferrara, M. Colden-Stanfield, X. Liu, S.S. Pierangeli (USA)

P168 Effects of an inhibitor of nuclear factor-kappa B (NF-kB) on thrombogenic properties of antiphospholipid antibo-dies in vivoG. Montiel-Manzano, Z. Romay-Penabad, E. Papalardo, S.S. Pierangeli (USA)

P169 Domain I of ß2-glycoprotein I ameliorates thrombosis induced by antiphospholipid antibodies in miceJ. Iaonnou, T. Harper, Z. Romay-Penabad, I.P. Giles, C. Pericleous, A. Rahman, X. Liu, S.S. Pierangeli (UK, USA)

P170 A dimer of ß2glycoprotein I (ß2GPI) upregulates tissue factor (TF) and is thrombogenic in vivoZ. Romay-Penabad, R.T. Urbanus, M.T. Pennings, G. Montiel-Manzano, P.G. de Groot, S.S. Pierangeli(USA, The Netherlands)

P171 Platelets express three 3 different splice variants of ApoER2 of which ApoER2∆4-5 is the most abundant. Dimeric ß2-GPI binds to LDL-binding domain 1 of ApoER2M.T.T. Pennings, R.H.W.M. Derksen, R.T. Urbanus, P.G. de Groot (The Netherlands)

P172 ADAMTS13 dysfunction and anti-ADAMTS13 antibodies in the antiphospholipid syndrome (APS)S.K. Austin, R.D. Starke, A.S. Lawrie, H. Cohen, S.J. Machin, I.J. Mackie (UK)

P173 Evaluation of isolated anti beta 2 glicoprotein IM.T. Mascia, A. Melegari, F. De Gennaro, G. Sandri, L. Simoni, A. Carbonieri (Italy)

P174 8-Hydroxy-2'-deoxyguanosine has an inhibitory effect on Rac activity of mouse macrophageS. Lee, S.Choi, M-H. Chung (Korea)

P175 Anti-ß2-GPI antibodies induce monocyte release of TNFa and tissue factor by signal transduction pathways involving lipid raftsC. Alessandrì, M. Sorice, A. Longo, A. Capozzi, T. Garofalo, R. Misasi, F. Conti, C. Croia, B. Buttari, R. Biganò, E. Ortona, G. Valesini (Italy)

P176 Pregnancy outcome in women with inherited/acquired thrombophiliaB. Teruzzi, E. Rossi, L. Arrigoni, V. Gerloni, F. Fantini (Italy)

P177 Pregnancy outcome in lupus pregnant women with antiphospholopid antibodies F. Mecacci, B. Bianchi, A. Pieralli, R. Cioni, L. Giorgi, C. Buzzoni, A. Mangani, G. Mello (Italy)

P178 A novel surface plasmon resonance biosensor for the analysis of antiphospholipid antibodiesP.B. Luppa, J. Metzger (Germany)

P179 Role of antibodies recogizing oxidixed phospholipids in laboratory tests exploring lupus anticoagulant activityR. Rolla, M. Vidali, R. Serino, P. Pergolini, E. Albano, G. Bellomo (Italy)

P180 European multicenter evaluation of the ELISA for anti-phosphatidylethanolamine antibodiesM. Sanmarco, G. Reber, A. Béziane, U. Gaipl, B. Gilburd, G. Massai, M. Meissner, Z. Ulcova-Gallova, D. Ponard, M.C. Boffa (France, Switzerland, Germany, Israel, Italy, Poland, Czech)

P181 Antiphospholipid antibodies in women experiencing repeated in vitro fertilization failuresM. Sanmarco, N. Bardin, L. Camoin, G. Porcu (France)

32


*progr antifosfolidi - aps · general information venue palazzo dei congressi p.zza adua, 1 50123...

Documents